Cellosaurus cell line HCC2185 (CVCL_3375)

PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L., Sakaguchi M., Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I., Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
Int. J. Cancer 78:766-774(1998)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25757734; DOI=10.1186/s13058-015-0517-z
Christgen M., Derksen P.W.B.
Lobular breast cancer: molecular basis, mouse and cellular models.
Breast Cancer Res. 17:16.1-16.9(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)